Autonom kunstig intelligens versus AI-assistert menneskelig optisk diagnose (CADx-Prosp)
Autonom kunstig intelligens versus AI-assistert menneskelig optisk diagnose av kolorektale polypper: en randomisert kontrollert prøvelse
Computer-aided image-enhanced endoscopy can predict the nature of colorectal polyps with over 90% accuracy. This technology uses artificial intelligence (AI) to analyze video recordings of polyps, learning to make diagnoses in real-time. This means that doctors can get immediate predictions about small polyps during the procedure, reducing the need for separate pathology exams and saving costs, ultimately improving patient care.
Human and AI interactions are complex and a framework to reap synergistic effects CADx systems when used by humans to harness optimal performance needs to be established. AI solutions in medicine are usually developed to be used as assistive devices, however, then they rely on humans to correct AI errors. Optical polyp diagnosis is a complex task. Non experts usually achieve diagnostic accuracy in 70-80%. CADx systems have a similar diagnostic accuracy when used autonomously. Clinical evaluation of CADx systems showed that CADx assisted OD performs equally to the operator performance when using non CADx assisted OD. To harness a benefit of clinical CADx implementation we would have to find a way that synergies between human and CADx come into play to eliminate cases in which CADx assisted and/ or human OD results in low diagnostic accuracy and also addresses the problem of serrated polyp recognition.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Our study hypothesis is that for CADx implementation, instead of using the high/low confidence framework, identifying cases with suboptimal diagnostic accuracy could be facilitated through identifying cases in which CADx and endoscopist disagreed in their diagnosis. Eliminating such cases might separate out cases with low accuracy when using CADx assisted OD. Since endoscopists have a high sensitivity but low specificity for serrated polyp OD, this framework will also allow us to implement a strategy to adequately manage serrated polyps found in the cohort.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Daniel von Renteln, MD
- Telefonnummer: 30912 514 890-8000
- E-post: daniel.von.renteln.med@ssss.gouv.qc.ca
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada
- Rekruttering
- Ghislaine Ahoua
-
Ta kontakt med:
- Daniel von Renteln, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Indication for full colonoscopy.
Exclusion Criteria:
- Known inflammatory bowel disease
- Active colitis
- coagulopathy
- familial polyposis syndrome
- poor general health, defined as an American Society of Anesthesiologists class >3
- emergency colonoscopy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: All participants
The endoscopist will make an optical diagnosis (OD) prediction for all small polyps (up to 10 mm) in white light (WL). Then, the endoscopist will make another OD prediction using image enhanced endoscopy (IEE) modes. After that, CADx will be activated in the IEE mode and a CADx prediction will be documented. Finally, after seeing the CADx prediction, the endoscopist will make a final prediction, which can agree or disagree with the autonomous CADx one. Polyps will be resected and sent to a pathology lab, where a pathologic diagnosis (blinded to the endoscopist's predictions) will be rendered. |
The CADx system will be used to predict the histopathology of the polyp detected. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accuracy of optical diagnosis, for polyps 1-5mm, compared with an agreed upon CADx-assisted diagnosis
Tidsramme: up to 100 weeks
|
Accuracy of optical diagnosis, for polyps 1-5mm, compared with an agreed upon CADx-assisted diagnosis , when histopathology results are used as the reference |
up to 100 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accuracy of optical diagnosis, for polyps 1-10mm, compared with an agreed upon CADx-assisted diagnosis
Tidsramme: up to 100 weeks
|
Accuracy of optical diagnosis, for polyps 1-10mm, compared with an agreed upon CADx-assisted diagnosis, when histopathology results are used as the reference |
up to 100 weeks
|
|
Test characteristics, including recall, specificity, positive and negative predictive values (PPV/NPV), and particularly the NPV of rectosigmoid neoplastic polyps.
Tidsramme: up to 100 weeks
|
A ≥90% NPV will be used as a quality benchmark for a strategy to not resect such diminutive polyps. |
up to 100 weeks
|
|
Agreement of surveillance interval recommendations of AI-A and AI-H compared with the pathology-based recommendations
Tidsramme: up to 100 weeks
|
For surveillance interval assignment, the pathology results of concomitant polyps >5 mm (including multiple concomitant polyps of all sizes and histology) will be considered when calculating the surveillance interval recommendation. Surveillance recommendations will be based on the 2020 United States Multi Society Task Force Guidelines as is current standard of practice at our center. |
up to 100 weeks
|
|
Proportion of patients for whom an immediate surveillance recommendation can be directly provided for each approach, and how often histopathology-based polyp examination would have been avoided.
Tidsramme: up to 100 weeks
|
The potential cost-effectiveness of OD (either approaches) will be evaluated using the measured described above. |
up to 100 weeks
|
|
Variability of OD (AI-A and AI-H) across participating endoscopists.
Tidsramme: up to 100 weeks
|
Each participating endoscopist will conduct a similar number of optical diagnoses to assess endoscopist-related factors. |
up to 100 weeks
|
|
Cost-effectiveness of OD ((AI-A and AI-H)
Tidsramme: up to 100 weeks
|
A cost-effectiveness model will be applied to better quantify costs and understand cost impact including key cost drivers when generalized to a broader screening population. |
up to 100 weeks
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Daniel von Renteln, MD, University of Montreal Medical Center (CHUM)
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2025-12306
- 2025 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .